Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADCT Stock: 10.41% Increase Explanation
07:04pm, Monday, 26'th Apr 2021
The stock price of ADC Therapeutics SA (NYSE: ADCT) increased by 10.41% today. This is why it happened.
ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment
06:12am, Monday, 26'th Apr 2021
ADC Therapeutics SA (NYSE: ADCT) has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients with relapsed or refractory diffuse large
3 Stocks At 52-Week Lows That Could Bounce Big
05:15pm, Wednesday, 31'st Mar 2021
One trading strategy an investor can profitably employ is to pick up an undervalued asset that has sold off due to factors that are extraneous or intrinsic to it. The strategy is premised on the belie
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates
07:00am, Thursday, 18'th Mar 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and ta
ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021
07:15am, Thursday, 11'th Mar 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season
09:52am, Wednesday, 03'rd Mar 2021
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
07:15am, Thursday, 25'th Feb 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
07:15am, Friday, 05'th Feb 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
ADC Therapeutics SA (ADCT) Upgraded to Buy: Here's Why
12:48pm, Thursday, 21'st Jan 2021
ADC Therapeutics SA (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event
07:15am, Monday, 04'th Jan 2021
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
Week In Review: Week's China Life Science Investments Total $800 Million
03:01pm, Sunday, 20'th Dec 2020
Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing a
LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, toda
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
